Vanda Pharmaceuticals
VNDA
148 hedge funds and large institutions have $246M invested in Vanda Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 44 increasing their positions, 46 reducing their positions, and 34 closing their positions.
24% more capital invested
Capital invested by funds: $198M → $246M (+$47.7M)
12% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 34
3% more funds holding
Funds holding: 144 → 148 (+4)
4% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 46
8.89% less ownership
Funds ownership: 83.69% → 74.8% (-8.9%)
40% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $2.04M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$5.97M |
| 2 |
KAM
Krensavage Asset Management
New York
|
+$3.42M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.07M |
| 5 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$5.84M |
| 2 |
D.E. Shaw & Co
New York
|
-$5.73M |
| 3 |
Morgan Stanley
New York
|
-$5.22M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.98M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HFS
176
Hantz Financial Services
Southfield,
Michigan
| – | -$6K | -1,500 | Closed |
|
|
MLICM
177
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$6.05K | -1,471 | Closed |
|
|
ACM
178
Aquatic Capital Management
Chicago,
Illinois
| – | -$1.23K | -300 | Closed |
|
|
C
179
Covestor
London,
United Kingdom
| – | -$1K | -286 | Closed |
|
180
First Manhattan
New York
| – | -$411 | -100 | Closed |
|
|
AWM
181
Avior Wealth Management
Omaha,
Nebraska
| – | -$41 | -10 | Closed |
|
VNDA Hedge Fund Activity: Q2 2024 in Review
148 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q2 2024, worth a combined $246M — up 24% from $198M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new VNDA positions and 34 closed out — a net gain of 4 holders — while 44 added to existing stakes and 46 trimmed.
The largest buyer was Schroder Investment Management Group, opening a new position worth an estimated $5.97M. The largest seller was Bank of America, cutting an estimated $5.84M.
- 148 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q2 2024, up from 144 in Q1 2024.
- Funds reported $246M of Vanda Pharmaceuticals stock for Q2 2024, up 24% quarter-over-quarter.
- 38 funds opened new Vanda Pharmaceuticals positions in Q2 2024 and 34 closed out, a net change of +4 holders.
- The largest Vanda Pharmaceuticals buyer in Q2 2024 was Schroder Investment Management Group, an estimated $5.97M added.
- The largest Vanda Pharmaceuticals seller in Q2 2024 was Bank of America, an estimated $5.84M sold.
Based on aggregated 13F filings for Q2 2024.